Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Staar Surgical ( (STAA) ) has shared an update.
On June 18, 2025, STAAR Surgical Company held its Annual Meeting of Shareholders where three proposals were voted upon. The shareholders elected six directors for terms expiring at the 2026 Annual Meeting, ratified the appointment of BDO USA, P.C. as the independent accounting firm for the fiscal year ending January 2, 2026, and approved the compensation of the Company’s executive officers on a non-binding advisory basis.
The most recent analyst rating on (STAA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The overall stock score reflects significant challenges in financial performance with declining revenues and negative margins as the most impactful factors. While corporate events and strategic initiatives provide a positive outlook, technical indicators and valuation metrics caution about potential risks. The company needs to address operational and profitability issues to improve investor sentiment.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company operates in the medical device industry, focusing on the development, manufacture, and marketing of implantable lenses for the eye, primarily for vision correction.
Average Trading Volume: 898,474
Technical Sentiment Signal: Sell
Current Market Cap: $841.4M
See more insights into STAA stock on TipRanks’ Stock Analysis page.